SLC5A2 rs9927250: Heart Failure Outcomes and Genetic Variation
The rs9927250 variant is a genetic polymorphism located within the SLC5A2 gene. Research has identified this variant as being associated with clinical outcomes in patients with heart failure, particularly in the context of treatment with SGLT2 inhibitor medications.
What each genotype means
Common genetic variant
This is the most frequently observed genotype for this variant in many populations. Research indicates that this variant in the SLC5A2 gene is associated with clinical outcomes in heart failure patients, though it is not a diagnostic marker. Please discuss your overall heart health and any medication management with your clinician or pharmacist.
This is the most common genotype observed in study cohorts, such as the one reported in recent heart failure research.
Heterozygous variant carrier
You carry one copy of the variant allele. Studies have examined this variant in the context of heart failure outcomes and response to SGLT2 inhibitor medications. This finding should be discussed with your healthcare provider to understand how it fits into your broader clinical picture and treatment plan.
This genotype is found in a significant minority of individuals within studied heart failure cohorts.
Homozygous variant carrier
You carry two copies of the variant allele. Research suggests that variations in the SLC5A2 gene may influence clinical outcomes in heart failure patients. Because this is a complex genetic association, please consult with your doctor or pharmacist regarding your specific health status and any prescribed medications.
This is the least common genotype observed in the studied heart failure populations.
Understanding the rs9927250 Variant
The rs9927250 variant is a single nucleotide polymorphism (SNP) found within the SLC5A2 gene. In genetics, a SNP represents a variation at a single position in a DNA sequence among individuals. This specific variant has been identified in scientific literature as one of several polymorphisms within the SLC5A2 gene that may influence how patients with heart failure respond to clinical interventions. Researchers often study such variants to understand why individuals may experience different health outcomes or drug responses, even when diagnosed with the same condition. By analyzing these genetic markers, scientists aim to uncover the biological mechanisms that contribute to disease progression and the efficacy of various therapeutic strategies.
The Role of the SLC5A2 Gene
The SLC5A2 gene provides instructions for producing the sodium-glucose cotransporter 2 (SGLT2) protein. This protein is primarily responsible for reabsorbing glucose from the urine back into the bloodstream in the kidneys. Because of its critical role in glucose regulation, the SLC5A2 gene is the primary target for a class of medications known as SGLT2 inhibitors. These drugs are widely used to manage blood sugar levels in patients with type 2 diabetes and have also become a standard treatment for heart failure. Variations in the SLC5A2 gene, such as rs9927250, are of interest to researchers because they may potentially alter the expression or function of the SGLT2 protein, which could theoretically influence how a patient's body interacts with these medications.
Research Associations and Evidence
Recent studies have investigated the relationship between SLC5A2 variants and clinical outcomes in heart failure patients. Specifically, research has examined how these variants correlate with the risk of hospitalization or cardiovascular death. In some analyses, rs9927250 has been associated with differences in clinical outcomes among patients who are either naive to SGLT2 inhibitor treatment or currently receiving it. It is important to note that while these statistical associations are observed in research cohorts, the evidence is considered moderate. The field is still actively investigating whether these genetic markers can reliably predict individual drug responses. Because heart failure is a complex condition influenced by many genetic and environmental factors, these findings should be viewed as part of an evolving body of research rather than definitive clinical predictors.
Population Frequency
The rs9927250 variant is considered a common genetic polymorphism. In many study populations, researchers observe a distribution of the different genotypes (G/G, G/A, and A/A) that allows for statistical comparison. Because it is common, it is frequently included in genetic risk analyses and large-scale association studies. The frequency of the specific alleles can vary across different ancestral backgrounds, which is a standard observation for many common SNPs. Understanding this frequency is essential for researchers to ensure that their findings are robust and applicable across diverse groups of people.
Interpreting Genetic Information
If you have information about your genotype for rs9927250, it is important to understand that this data is for educational purposes only. Genetic associations identified in research studies describe trends across large groups of people and do not provide a diagnosis or a personalized medical prognosis for an individual. You cannot use this information to make decisions about your medications or treatment plans. If you are currently taking SGLT2 inhibitors or are concerned about your heart health, you must discuss your medical history, genetic testing results, and any questions about your treatment with your clinician or pharmacist. They are the only ones qualified to interpret how your specific health profile relates to your care and to adjust your medication dosing if necessary.
How common is this variant?
The rs9927250 variant is a common polymorphism found across various human populations, with researchers typically observing a mix of homozygous and heterozygous genotypes in study cohorts.
Frequently asked questions
What is the SLC5A2 gene?
The SLC5A2 gene encodes the SGLT2 protein, which helps the kidneys reabsorb glucose. It is the primary target for SGLT2 inhibitor medications used in treating heart failure and type 2 diabetes.
Does rs9927250 affect my heart failure medication?
Research is ongoing regarding how SLC5A2 variants like rs9927250 might influence drug response. Currently, these findings are statistical associations in research studies and should not be used to change your medication without consulting your doctor.
Is rs9927250 a diagnostic test for heart failure?
No, rs9927250 is not a diagnostic test. Heart failure is a complex condition diagnosed by healthcare professionals using clinical evaluations, imaging, and blood tests, not by a single genetic variant.
Where can I find more information on this SNP?
You can find technical data on this variant through public databases like the NCBI SNP database (dbSNP) or the GWAS Catalog. These resources provide detailed information on the research studies that have investigated this specific genetic marker.
Sources & further reading
Educational information only, last refreshed 10/27/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs9927250?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in SLC5A2
A variant in the SGLT2 gene associated with clinical outcomes and response to dapagliflozin in heart failure patients.
This variant in the SLC5A2 gene is associated with clinical outcomes and response to dapagliflozin in patients with heart failure.
This SNP in the SLC5A2 gene has been identified as a factor influencing clinical outcomes in patients treated with SGLT2 inhibitors.